Key clinical point: Researchers have demonstrated that dasatinib is able to transiently inhibit CAR T-cell activity in mice, suggesting applicability as an on-off control for CAR T-cell therapy.
Major finding: The dose of dasatinib was titratable to attain either partial or complete inhibition of CAR T-cell antitumor function.
Study details: A preclinical study exploring the pharmacological effects of dasatinib on CAR T cells.
Disclosures: The study was funded by the Cluster Biotechnologie Bayern and Free State of Bavaria, the German Cancer Aid, and the University of Würzburg. The authors reported financial affiliations with Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda, and others.
Mestermann K et al. Sci Transl Med. 2019 Jul 3. doi: 10.1126/scitranslmed.aau5907.